AgenTus Management Team

Bruno Lucidi Chief Executive Officer

Bruno Lucidi is CEO of AgenTus. Bruno joins AgenTus with more than 30 years of experience in the biopharmaceutical industry with expertise in advancing successful products from discovery to market. Lucidi’s leadership record includes Vice President and Head of Pediatric Vaccines at GSK Biologicals, where he was in charge of developing a global business of more than $3 billion. He also served as Worldwide Vice-President Virology & Oncology at Johnson & Johnson, in charge of the portfolio strategy and advancement. Prior to his time at J&J, Bruno held various leadership positions in oncology drug development at Bristol-Myers Squibb where he led the European Virology and Oncology team and was responsible for the strategy and launch of several antiviral and oncology new products, including but not limited to Videx® (didanosine), Zerit® (stavudine), Paraplatin® (carboplatin) and Taxol® (paclitaxel). Lucidi was the Founding CEO of Idenix and the Chairman of Pharmasset, where his contributions at both companies laid the foundation for multi-billion dollar companies, which were later acquired by Merck and Gilead for nearly $4bn and $11bn respectively. Lucidi also served as CEO of several companies in Europe including Karolinska Development AB (Nasdaq Stockholm: KDEV), KDEV Oncology, Aprea AB (Sweden) and Endotis SA (France). Currently, Lucidi serves as an External Expert for the European Commission and Life Sciences Expert at AWEX, Wallonia trade and foreign investment agency in Belgium.

Mark Exley, Ph.D. Cellular Immunology

Mark Exley, Ph.D. leads cellular immunology at AgenTus, and is an expert on the biology and clinical exploitation of NKT and other immune cells. He co-developed anti-NKT monoclonal antibodies used in clinical trials, one of which was published in 2017 (Clin. Cancer Res.). Dr. Exley’s areas of research have included: (i) immunity to cancers: natural anti-tumor immunity and how to optimize responses directly and through vaccines, (ii) protective versus inflammatory immune responses to acute and chronic viral infections, and (iii) cells involved in suppressing graft-versus-host disease, obesity-associated and other inflammations. Dr. Exley has published over 120 mostly peer-reviewed articles in scientific journals, as well as reviews and book chapters, and serves on editorial boards of many journals, as Associate Editor of Clin. Immunol. He has received numerous research awards and grants from federal and other agencies. Dr. Exley was Faculty at Harvard Medical School, where he was co-founder of NKT Therapeutics Inc., and Professor at University of Manchester, UK. He retains honorary appointments at both institutions. Dr. Exley completed his post-doctoral fellowship at the Dana Farber Cancer Institute, Harvard Medical School and was a Scientist at Immulogic Inc. He received his BS from Imperial College, London and his Ph.D. from the Institute of Cancer Research, London.

Cori Gorman, Ph.D. Precision Medicine and Manufacturing

Cori Gorman, Ph.D. leads precision medicine and manufacturing for AgenTus and Agenus. With 25 years of experience in the biotechnology industry, Dr. Gorman has worked in all aspects of the biotechnology industry, including raising capital, strategic planning and developing infrastructure. She has helped early stage biotechnology companies raise over $80 million (federal funds and VCs) and has closed over 25 partnerships in a corporate development capacity. She has used this experience to chair numerous sessions on business models and financing for early stage companies at BIO and Bio-Europe conferences. She has been a guest lecturer on the business of biotechnology at Yale and at Haas Business School, UC Berkeley. Prior to Agenus, Dr. Gorman served as the CEO of a Swiss based biosimilar company whose drugs are entering the market in Southeast Asia. Her experience in the biotechnology industry includes a ten-year period at Genentech where she helped to develop numerous marketed products including Kogenate, Activase, Herceptin, Xolair, and Raptiva. Based on her work at Genentech, Dr. Gorman is recognized as a pioneer in the development of monoclonal antibody therapeutics and has co-authored six Investigational New Drug Applications (INDs). Upon leaving her position at Genentech, Dr. Gorman co-founded two biotech start-ups, one of which, Valentis, went public. Dr. Gorman has an outstanding record of achievement in basic research and drug development. She is an inventor on nine issued patents in the fields of gene expression and delivery and gene therapy and is recognized as one of the most highly cited people in her field in the last two decades. Dr. Gorman developed the CAT assay, which was the industry standard for more than fifteen years. Her scientific work has received over 20,000 citations. Dr. Gorman has received several fellowships from such organizations as the American Cancer Society, the National Cancer Institute, the European Molecular Biology Organization and NATO.

Andy Hurwitz, Ph.D. Preclinical Research

Andy Hurwitz, Ph.D. leads preclinical research for AgenTus and Agenus where he is responsible for the preclinical evaluation of TCR candidates identified in the Cell Therapy Program as well as translational development of heat shock protein-based vaccines. He is an expert in T cell responses to antigens relevant to cancer and autoimmune disease. Prior to Agenus, Dr. Hurwitz was a Principal Investigator in the Cancer and Inflammation Program at the National Cancer Institute (NIH). His laboratory developed several TCR-based experimental models used to study T cell tolerance to tumor antigens. Dr. Hurwitz received his Ph.D. from the Albert Einstein College of Medicine and did his postdoctoral training at University of California, Berkeley.  Prior to the NIH, he was on the faculty at SUNY Upstate Medical University.

Marc van Dijk, Ph.D. Platform Development

Marc van Dijk, Ph.D. leads platform development for AgenTus and Agenus, and heads the Agenus UK site. Previously, he served as Chief Technology Officer of 4-Antibody, a subsidiary of Agenus, where he developed Retrocyte Display™, Agenus’ proprietary antibody discovery platform. In this role, Dr. van Dijk led the antibody discovery programs in the alliance with the Ludwig Institute for Cancer Research branch, New York, including CTLA4, PD1, GITR and OX40, the resulting antibodies of which are now in clinical development. Dr. van Dijk was Director of Applied Research at Innogenetics (now Fujirebio) and Vice President, Antibody Technology at Genmab. During his time at the European R&D facility of Medarex Inc., Dr. van Dijk served as a Principal Scientist. He was involved in the set up and management of partnerships with Immunex (now Amgen), and Roche, and served as project leader on numerous discovery projects including Humax-CD20 (Arzerra™, Novartis). Dr. van Dijk held a tenure track position in the Department of Immunology at the University Medical Center in Utrecht, and completed his postdoctoral fellowship in Molecular Biology at the University of California, San Diego. He obtained his Ph.D. in Molecular Biology from Utrecht University in 1992.

Board of Directors

Garo Armen Chairman of the Board

Garo serves as Chairman and Chief Executive Officer of Agenus Inc., and Chairman of the Board of AgenTus. Under his leadership, Agenus has been advancing breakthrough scientific technologies and immunotherapeutic products for 20 years. From mid-2002 through 2004, Garo, in addition to his responsibilities at Agenus, served as Chairman of the Board of Directors for the biopharmaceutical company Elan Corporation, plc, which he successfully restructured. Garo serves as non-executive Chairman of the Board of Protagenic Therapeutics, a biotechnology company focusing on human brain hormones for the treatment of neurological and metabolic disorders. He also serves as Founder and Chairman of the Children of Armenia Fund (COAF), a philanthropic organization he founded in 2000; COAF is dedicated to the development of children and youth in Rural Armenia. He received his PhD in physical chemistry from the City University of New York.)

Brian Corvese

Mr. Corvese is president and founder of Vencor Capital, a private equity firm with telecommunications and technology investments in the Middle East and Mediterranean regions. Prior to Vencor, Mr. Corvese worked on investments in the US and global equity markets as a managing director and partner at Soros Fund Management, the largest hedge fund in the world at the time. From 1988 to 1996, Mr. Corvese was a partner at Chancellor Capital Management, a $25-billion money management firm. While at Chancellor, Mr. Corvese was a portfolio manager with responsibility for investments made in basic industries, restructurings, and special situations, corporate governance investments, as well as founding and managing his own hedge fund. From 1981 to 1988, Mr. Corvese was with Drexel Burnham Lambert as an equity analyst following the chemical and specialty chemical industries and he participated in a significant number of merger and acquisition activities. While at Drexel, Mr. Corvese was a member of the top chemical and specialty chemical research team, as ranked by Institutional Investor. Mr. Corvese currently serves on the board of the National Telecommunications Company, based in Cairo, Egypt. Mr. Corvese earned degrees in finance and political science from The University of Rhode Island and attended New York University Graduate School.

Bruno Lucidi Chief Executive Officer

Bruno Lucidi is CEO of AgenTus. Bruno joins AgenTus with more than 30 years of experience in the biopharmaceutical industry with expertise in advancing successful products from discovery to market. Lucidi’s leadership record includes Vice President and Head of Pediatric Vaccines at GSK Biologicals, where he was in charge of developing a global business of more than $3 billion. He also served as Worldwide Vice-President Virology & Oncology at Johnson & Johnson, in charge of the portfolio strategy and advancement. Prior to his time at J&J, Bruno held various leadership positions in oncology drug development at Bristol-Myers Squibb where he led the European Virology and Oncology team and was responsible for the strategy and launch of several antiviral and oncology new products. Lucidi was the Founding CEO of Idenix and the Chairman of Pharmasset, where his contributions at both companies laid the foundation for multi-billion dollar companies, which were later acquired by Merck and Gilead for nearly $4bn and $11bn respectively. Lucidi also served as CEO of several companies in Europe including Karolinska Development AB (Nasdaq Stockholm: KDEV), KDEV Oncology, Aprea AB (Sweden) and Endotis SA (France). Currently, Lucidi serves as an External Expert for the European Commission and Life Sciences Expert at AWEX, Wallonia trade and foreign investment agency in Belgium.

Ulf Wiinberg

Mr. Wiinberg has 20 years of senior leadership experience, most recently serving as Chief Executive Officer of H. Lundbeck A/S, a global pharmaceutical company developing and marketing treatments for psychiatric and neurological disorders. He previously served on the boards of several healthcare industry associations and held multiple executive roles at Wyeth, one of the world’s largest research-driven pharmaceutical companies that was acquired by Pfizer in 2009. He served as President of Wyeth Europe, Africa and Middle East; President of Consumer Healthcare; Managing Director of Wyeth UK, and in various commercial positions. Mr. Wiinberg currently serves on the boards of UCB SA, a global biopharmaceutical company based in Belgium, Avillion LLP (Chairman), a London-based drug development company, Hansa Medical AB (Chairman), a Swedish biopharmaceutical company, Alfa Laval AB, a Swedish industrial company, and Nestle Health Science.

Scientific Advisors

Robert Stein, MD, PhD Senior R&D Advisor

Dr. Robert Stein has over 35 years of experience and accomplishments in the pharmaceutical and biotech industry and advises Agenus’ global research and development efforts. Bob previously served as the Company’s President of R&D. Over the course of his career, Bob has played a significant role in the discovery and development of eight marketed drugs, including Sustiva®, Fablyn®, Viviant®, PanRetin®, TargRetin®, Promacta®, & Eliquis®. Prior to working at Agenus, he held a number of progressively responsible senior management positions including Head of Pharmacology for Merck & Co., CSO & SVP of Research for Ligand Pharmaceuticals, EVP of Research & Preclinical Development for Dupont Merck, President and CSO for Incyte Pharmaceuticals, President of Roche Palo Alto, and CEO of KineMed. Bob spent the early part of his career at Merck, Sharp and Dohme Research Laboratories. He holds an MD and a PhD in Physiology & Pharmacology from Duke University.

Andres McAllister Strategic Advisor

Andres McAllister Ph.D. serves as Strategic Advisor to AgenTus. For the past two years, he has served as a consultant to the biotech and pharmaceutical industry, with particular focus on cancer immunotherapy. Before becoming a consultant, Dr. McAllister was Chief Scientific Officer at Debiopharm, where he led a team of medical doctors and scientists specializing in search, evaluation and early stage development of new projects with a strong interest in oncology and infectious diseases. His team supervised the evaluation of over 800 projects, and several due diligence exercises per year that resulted in successful in-licensing deals, and the acquisition of innovative molecules that are currently in advanced clinical development. Prior to Debiopharm, he served as Director of R&D at Immune Design Molecules, a biotechnology company specialised in immunotherapy and cell therapy of cancer. McAllister graduated from Medical School in 1984, and worked in infectious diseases during the early years of his medical career. In 1991, he obtained a Ph.D. in Molecular Virology at the Pasteur Institute in Paris. He continued his work at the Pasteur Institute, and the University of California, San Francisco, concentrating on the development of viral vectors and the use vaccine viruses to treat cancer. He worked at the Centre of Immunology Pierre Fabre near Geneva on the industrial development of this type of approach.

Back to Top